TXA and Corona Virus 2019 (COVID19) in Outpatients

Phase 2 Terminated 5 enrolled University of Alabama at Birmingham

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A controlled trial of the drug tranexamic acid (TXA) in outpatients who were recently diagnosed with COVID-19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.

Timeline

Start: 2020-06-01
Primary completion: 2021-04-21
Completion: 2021-04-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tranexamic Acid	Small molecule	1300 mg	Oral

TXA and Corona Virus 2019 (COVID19) in Outpatients

Summary

Timeline

Drugs

Indications